Vedanta Biosciences
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
19 Blackstone St, Cambridge, Massachuset...Phone Number
(857) 706-1427Website
www.vedantabio.comRevenue
$33.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Vedanta Biosciences
Founded in 2010, Vedanta Biosciences is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. The company designs medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies. The company is headquartered in Cambridge, Massachusetts.Explore more
Vedanta Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vedanta Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Vedanta Biosciences is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Vedanta Biosciences
Earning: See what the market has to say on Vedanta Biosciences recently announced quarterly report
Funding: Get notified immidiatlly once Vedanta Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Vedanta Biosciences launches new products
Vedanta Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Vedanta Biosciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if Vedanta Biosciences had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Vedanta Biosciences
Find 3 more new buyers
Compare Similar Companies to Vedanta Biosciences
Compare insights from companies similar to Vedanta Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vedanta Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vedanta Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vedanta Biosciences.
Vedanta Biosciences financials insights
Gather financial insights about Vedanta Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series B
$50M
2018
Series C
$27M
2020
Debt
$15M
2021
Corporate Investment
$25M
Series D
$68M
2023
Unspecified
$106.5M
2026
Other Financing Round
$60M
Vedanta Biosciences Tech Stack
A closer look at the technologies used by Vedanta Biosciences
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Facilities Relocation / Expansion
Vedanta Biosciences is planning to move offices in January 2027. The move will impact approximately 32 employees at the existing office located at 19 Blackstone Street, Cambridge, MA.
Facilities Relocation/Expansion
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Vedanta Biosciences News & Media
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
BOSTON--(BUSINESS WIRE)--PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature MedicineVedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published this month in Nature Medicine and can be viewed online. VE303 is a potential fVedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies with an initial focus on gastrointestinal diseases, today announced the oral presentation of additional analyses from its completed Phase 2 CONSORTIUM study of VE303, an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent Clostridioides difficile infection (rCDI). These analyses document theVedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases, today announced three appointments to its leadership team. Christof Marré, a seasoned biopharma marketing leader, joins the company as Senior Vice President and Head of Commercial. In addition, Steven Shiff, M.D., a pharmaceutical executive and physician specializing in gastroenterology, has been appointed as SVP, Clinical Resear
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Vedanta Biosciences
Sign Up For FreeTo access detailed company insights
Founded in 2010, Vedanta Biosciences is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. The company designs medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal... Read More
